Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02039817 · ClinicalTrials.gov registry record · Phase 1
PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers
A Phase 1 study, sponsored by Conatus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02039817: Completed Phase 1 study, sponsored by Conatus Pharmaceuticals.
NCT02039817 is a Phase 1 study that has completed, run by Conatus Pharmaceuticals. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02039817, a Phase 1 study, has completed, sponsored by Conatus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is an open-label, parallel-group study to compare the pharmacokinetics and pharmacodynamics of IDN-6556 following a single 50 mg oral dose of IDN-6556 in subjects with severe renal impairment and matched healthy volunteers with normal renal function.
Primary Outcome
Area under the plasma concentration curve (AUC) parameters include AUC0-12, AUCinf, AUClast
Interventions
- DRUG IDN-6556
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
What the finished NCT02039817 record still lists
NCT02039817 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 1 intervention - of which IDN-6556 is the first listed.
NCT02039817 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02039817 about?
NCT02039817 is a clinical study titled "PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers". This is an open-label, parallel-group study to compare the pharmacokinetics and pharmacodynamics of IDN-6556 following a single 50 mg oral dose of IDN-6556 in subjects with severe renal impairment and matched healthy volunteers with normal renal function.
What is the current status of trial NCT02039817?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2014-01. Estimated completion is 2014-04.
What interventions are being tested in trial NCT02039817?
The interventions under investigation include: IDN-6556 (DRUG).
Who is sponsoring clinical trial NCT02039817?
This trial is sponsored by Conatus Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02039817's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia